Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre)

• Faculty
• Scientific Programmes
• Annual Report
• Scientific Publications
• Research Projects
• International Affairs
• Animal Research

All Publications

Quick Search       Advanced Search

• Matheu A, Klatt P, Serrano M (2005). Regulation of the INK4A/ARF locus by HDAC inhibitors. J Biol Chem 280, 4233-4241.
• Tárrega C, Ríos P, Cejudo-Marín R, Blanco-Aparicio C, van den Berk L, Schepens J, Hendriks W, Tabernero L, Pulido R (2005). ERK2 shows a restrictive and locally selective mechanism of recognition by its tyrosine phosphatase inactivators not shared by its activator MEK1. J Biol Chem 280, 37885-37894.
• Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, Honrado E, Rodríguez R, Urioste M, Valle L, Díez O, Cigudosa JC, Dopazo J, Esteller M, Benitez J (2005). A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 11, 1146-1153.
• Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalbán C, Piris MA (2005). Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11, 1467-1473.
• Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium (2005). Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11, 5175-5175.
• Martinez-Torrecuadrada JL, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal J I (2005). Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11, 6280-6290.
• Melchor L, Alvarez S, Honrado E, Palacios J, Barroso A, Díez O, Osorio A, Benítez J (2005). The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors. Clin Cancer Res 11, 8577-8584.
• Martínez N, Sánchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernández I, Navarrete M, Jimeno J, Piris MA (2005). Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 4, 814-823.
• Franco S, Canela A, Klatt P, Blasco MA (2005). Effectors of mammalian telomere dysfunction: a comparative transcriptome analysis using mouse models. Carcinogenesis 26, 1613-1626.
• Margetts CD, Astuti D, Gentle DC, Cooper WN, Cascon A, Catchpoole D, Robledo M, Neumann HP, Latif F, Maher ER (2005). Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocr-Relat Cancer 12, 161-172.